Jubilant Life Sciences Ltd

(Formerly Jubilant Organosys Ltd.)

Regd. Off: Bhartiagram, Gajraula, Distt. Jyotiba Phoolay Nagar-244 223 (U.P.)

Audited Financial Results for the Year ended 31st March, 2011

(₹ in Lacs)

CONSOLIDATED RESULTS				Particulars	JUBILANT LIFE SCIENCES LTD.			
Quarter Ended March 31 (Unaudited)		Year Ended March 31 (Audited)			Quarter Ended March 31 (Unaudited)		Year Ended March 31 (Audited)	
2011	2010	2011	2010		2011	2010	2011	2010
89034	99183	343340	379113	**Net sales/Income from operations**	56039	60192	220089	245606
403	160	883	665	Other Operating Income	306	202	541	339
89437	99343	344223	379778	**Total income**	56345	60394	220630	245945
79518	80228	306812	311637	**Total expenditure**	49875	46208	186069	188920
(3048)	(4109)	(3880)	(2038)	a) (Increase)/Decrease in stock in trade and work in progress	(2730)	(3593)	(3131)	(1646)
6404	6579	24007	20185	b) Purchase of traded goods	5540	4771	21637	17531
30575	35287	112943	129043	c) Raw & process materials consumed	24920	27516	90143	105344
5076	6811	21188	23716	d) Stores, spares, chemicals, catalyst & packing material consumed	2214	3351	9424	11608
6360	5594	22404	22003	e) Power & fuel	5920	4997	20665	19946
2203	2154	6965	7238	f) Other manufacturing expenses	1528	1436	4895	5239
18299	18478	71842	74526	g) Staff cost	4813	4279	17317	17600
3314	3184	18010	12468	h) Depreciation	2597	1668	9991	6510
10335	6250	33333	24496	i) Other Expenditure (Selling, general & admin. Expenses-Including Exchange Loss/Gain)	5073	1783	15128	6788
9919	19115	37411	68141	**Operating profit before Other Income & Interest**	6470	14186	34561	57025
471	410	1296	1986	Other Income	301	277	514	1154
10390	19525	38707	70127	**Profit before Interest & Exceptional Items**	6771	14463	35075	58179
3227	3452	10506	15052	Interest (Net)	1703	1797	4625	9971
7163	16073	28201	55075	**Profit after Interest but before Exceptional Items**	5068	12666	30450	48208
1541	(169)	4142	3286	Exceptional items	528	2	455	2281
5622	16242	24059	51789	**Profit from Ordinary Activities before tax**	4540	12664	29995	45927
(539)	2711	1336	9594	Tax Expenses (Net)	(628)	3463	2032	9617
6161	13531	22723	42195	**Net profit from Ordinary Activities after tax**	5168	9201	27963	36310
-	-	-	-	Extraordinary Items (net of tax expenses)	-	-	-	-
(11)	(185)	(249)	49	Minority Interest	-	-	-	-
6172	13716	22972	42146	**Net profit after Minority Interest**	5168	9201	27963	36310
1593	1588	1593	1588	Paid-up share capital (Face value per share ₹ 1)	1593	1588	1593	1588
		215634	218546	Reserves (excluding revaluation reserve)			212466	215697
				Earnings per share before and after extraordinary items (Not annualized)				
3.87	9.29	14.42	28.56	**Basic (₹)**	3.25	6.23	17.56	24.60
3.50	8.03	13.04	24.66	**Diluted (₹)**	2.93	5.38	15.87	21.24
				Public shareholding				
84129115	83627751	84129115	83627751	- Number of shares (₹ 1 each)	84129115	83627751	84129115	83627751
52.82	52.67	52.82	52.67	- Percentage of shareholding	52.82	52.67	52.82	52.67
				Promoters and promoter group Shareholding				
				a) Pledged/Encumbered				
7531333	14245000	7531333	14245000	- Number of shares	7531333	14245000	7531333	14245000
10.02	18.95	10.02	18.95	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	10.02	18.95	10.02	18.95
4.73	8.97	4.73	8.97	- Percentage of shares (as a % of the total share capital of the company)	4.73	8.97	4.73	8.97
				b) Non-Encumbered				
67620691	60907024	67620691	60907024	- Number of shares	67620691	60907024	67620691	60907024
89.98	81.05	89.98	81.05	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	89.98	81.05	89.98	81.05
42.45	38.36	42.45	38.36	- Percentage of shares (as a % of the total share capital of the company)	42.45	38.36	42.45	38.36

Notes:

1. The Board has recommended a dividend of ₹ 2 per equity shares of ₹ 1 amounting to ₹ 3702 lacs, subject to approval in the Annual General Meeting.

2. The Scheme of Amalgamation and Demerger (Scheme) among Jubilant Life Sciences Ltd (formerly Jubilant Organosys Ltd), Specialty Molecules Ltd , Pace Marketing Specialties Ltd and Jubilant Industries Ltd (formerly Hitech Shiksha Ltd) became effective during the year on 15th November, 2010. Under the Scheme, Specialty Molecules Limited (SML) a wholly owned subsidiary of Jubilant Life Sciences Ltd (Company) and Pace Marketing Specialties Limited (PMSL) an exclusive contract manufacturer of adhesives for Consumer Product Division of the JLL amalgamated with the Company on 31st March 2010. The Agri and Performance Polymer Business of the Company had been demerged into Jubilant Industries Limited (JIL) on 1st April 2010 .

Effective, the Demerger appointed date i.e. 1st April 2010 till the Scheme becoming effective, the operations of JIL were run by the Company, for and on behalf of JIL, on trust and the economic benefit attributable to JIL has been passed on to it, in terms of the said Scheme. Since, the economic benefits under the Scheme have accrued from appointed date, the equity shares issued pursuant to the Scheme have also been considered from appointed date for the purpose of calculation of Earning Per Share.

3. The results for the current quarter and year ended 31st March , 2011 are for the businesses remaining with the Company, post amalgamation/demerger, after giving effect to the Scheme and accordingly, are not comparable with the previous quarter/ period.

4. Post demerger of Agri and Performance Polymer Business, as stated above the Company's management has identified only one segment viz.Pharmaceuticals and Life Sciences Products and Services (PLSPS) as reportable segment.

5. Depreciation for the period/year is not comparable with the corresponding previous period/year , as previous year numbers are net of reversal of cumulative depreciation necessitated due to change in the depreciation policy amounting to ₹ 779 Lacs (consolidated ₹ 1794 Lacs) for Q4-FY 2010 and ₹ 3116 Lacs (consolidated ₹ 6747 Lacs) for FY 2010 and current year depreciation is lower due to change in estimates of useful life -Rs.1829 lacs for Q4-FY2011 & FY 2011.

6. Exceptional items include :

i) Amortization of Foreign Currency Monetary Item Translation Difference Account-gain/(loss) ₹ 502 Lacs {Consolidated ₹ (88 Lacs)} for Q4-FY 2011 and ₹ 1026 Lacs {Consolidated ₹ (1279 Lacs)} for FY 2011.

ii) Mark to Market in respect of unassigned forward contracts/Interest rate swap outstanding at the period end resulting in gain/(loss) amounting to ₹ (45) Lacs (Consolidated ₹ 112 Lacs) for Q4-FY 2011 and ₹ (367 Lacs) {Consolidated ₹ (490 Lacs)} for FY 2011

iii) Provision towards impairment of investments/abandoned projects amounting to ₹ 956 lacs(Consolidated ₹ 1399 lacs) for Q4-FY 2011 and FY 2011.

iv) Restructuring Expenses etc of ₹ 29 Lacs (Consolidated ₹ 166 Lacs) for Q4-FY 2011 and ₹ 158 Lacs (Consolidated ₹ 974 Lacs) for the FY 2011.

7. Tax Expenses(Net) is after considering the MAT Credit Entitlement.

8. Information on investors complaints for the quarter (Nos.): Opening Balance - Nil, New -36 , Disposals -36, Closing Balance - Nil.

9. Previous year / periods figures have been regrouped/reclassified wherever necessary.

10. The above Financial results were approved by the Board of Directors at its meeting held on 10th May, 2011

Place : Noida

Dated : 10th May, 2011

For Jubilant Life Sciences Ltd.

Shyam S Bhartia

Chairman & Managing Director

Jubilant Life Sciences Ltd.

(Formerly Jubilant Organosys Ltd.)

Segment wise Revenue, Results & Capital Employed

(under Clause 41 of the Listing Agreement)

Audited Financial Results for the year ended 31st March, 2011

(₹ in Lacs)

CONSOLIDATED RESULTS				Particulars	JUBILANT LIFE SCIENCES LTD			
Quarter Ended March 31 (Unaudited)		Year Ended March 31 (Audited)			Quarter Ended March 31 (Unaudited)		Year Ended March 31 (Audited)	
2011	2010	2011	2010		2011	2010	2011	2010
				Segment revenue				
89034	89978	343340	337503	a. Pharmaceuticals and Life Sciences Products & Services	56039	51042	220089	204139
-	9293	-	42064	b. Agri & Performance Polymers	-	9238	-	41921
89034	**99271**	**343340**	**379567**	**Total**	**56039**	**60280**	**220089**	**246060**
-	88	-	454	Less : Inter segment revenue	-	88	-	454
89034	**99183**	**343340**	**379113**	**Net sales/Income from operations**	**56039**	**60192**	**220089**	**245606**
89034	89890	343340	337049	a. Pharmaceuticals and Life Sciences Products & Services	56039	50954	220089	203685
-	9293	-	42064	b. Agri & Performance Polymers	-	9238	-	41921
89034	**99183**	**343340**	**379113**	**Total**	**56039**	**60192**	**220089**	**245606**
				Segment results (profit(+)/loss(-) before tax and interest from each segment)				
12500	20437	45722	75130	a. Pharmaceuticals and Life Sciences Products & Services	8819	15359	42021	63172
-	1012	-	1899	b. Agri & Performance Polymers	-	1026	-	1908
12500	**21449**	**45722**	**77029**	**Total**	**8819**	**16385**	**42021**	**65080**
3227	3452	10506	15052	Less : i Interest	1703	1797	4625	9971
3934	1755	11603	12250	i. Other un-allocable expenditure(including exceptional items)	3903	1925	8942	11244
(283)	(1)	(446)	(2062)	ii. Un-allocable Income(including exceptional items)	(1327)	(1)	(1541)	(2062)
5622	**16242**	**24059**	**51789**	**Total profit before tax**	**4540**	**12664**	**29995**	**45927**
				Capital Employed (Segment assets less Segment liabilities)				
525446	469012	525446	469012	a. Pharmaceuticals and Life Sciences Products & Services	227298	178632	227298	178632
-	21481	-	21481	b. Agri & Performance Polymers	-	21344	-	21344
525446	**490493**	**525446**	**490493**	**Total capital employed in segments**	**227298**	**199976**	**227298**	**199976**
105534	68739	105534	68739	Add: Un-allocable corporate assets less liabilities	304684	238448	304684	238448
630980	**559232**	**630980**	**559232**	**Total capital employed in the Company**	**531982**	**438424**	**531982**	**438424**

Jubilant Life Sciences Ltd

Regd. Off: Bhartiagram, Gajraula, Distt. Jyotiba Phoolay Nagar-244 223 (U.P.)

Audited Financial Results for the Year ended 31st March, 2011

Statement of Assets And Liabilities

(₹ in Lacs)

CONSOLIDATED RESULTS		Particulars	JUBILANT LIFE SCIENCES LTD.	
As at March 31 (Audited)			As at March 31 (Audited)	
2011	2010		2011	2010
		Share holders Funds		
1593	1588	a) Capital	1593	1588
215634	218546	b) Reserves and Surplus	212466	215697
4181	3792	Minority Interest	-	-
388416	311999	Loan from Banks, Institutions and FCCB's	298933	201227
4036	5273	Loan from Customers	-	-
21070	23495	Deferrec Tax Liabilities(Net)	18990	20498
534930	564693	**TOTAL**	531982	439010
466881	432452	Fixed Assets	196391	173144
-	22371	Investments-In Liquid Funds	-	18622
3275	3270	Investments-Others	186405	168298
3950	4253	Deferred Tax Assets(Net)	-	-
-	1208	Foreign Currency Monetary Items Translation Difference Account(FCMITDA)	-	586
		Current Assets , Loans and Advances		
69128	69095	a) Inventories	40470	42471
52045	51861	b) Sundry Debtors	33452	30730
104569	50367	c) Cash and Bank balances	98526	43422
-	-	d) Other current assets	-	-
56537	51827	e) Loans and Advances	71822	58434
		Less : Current Liabilities and Provisions		
78614	75352	a) Liabilities	54483	51955
42841	46659	b) Provisions	40601	44742
-	-	Miscellaneous Expenditure (Not Written Off or Adjusted)	-	-
634930	564693	**TOTAL**	531982	439010